Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 31934 | 11.18 |
09:34 ET | 2300 | 11.1 |
09:36 ET | 2700 | 11.07 |
09:38 ET | 200 | 11.085 |
09:39 ET | 650 | 11.055 |
09:41 ET | 3494 | 11.1 |
09:43 ET | 1845 | 11.03 |
09:45 ET | 350 | 11.035 |
09:48 ET | 3541 | 10.98 |
09:50 ET | 100 | 10.96 |
09:52 ET | 6299 | 10.97 |
09:54 ET | 9354 | 10.95 |
09:56 ET | 30283 | 11.06 |
09:57 ET | 100 | 11.055 |
09:59 ET | 1315 | 11.01 |
10:01 ET | 7398 | 11.1 |
10:03 ET | 1017 | 11.02 |
10:06 ET | 100 | 11.03 |
10:08 ET | 100 | 11.04 |
10:12 ET | 355 | 11.04 |
10:14 ET | 545 | 11.04 |
10:15 ET | 400 | 11.06 |
10:17 ET | 860 | 11.07 |
10:19 ET | 100 | 11.085 |
10:21 ET | 100 | 11.0775 |
10:24 ET | 400 | 11.05 |
10:26 ET | 300 | 11.04 |
10:28 ET | 1800 | 11.1 |
10:30 ET | 1415 | 11.1 |
10:32 ET | 500 | 11.08 |
10:33 ET | 967 | 11.01 |
10:35 ET | 1548 | 11.04 |
10:37 ET | 326 | 11.045 |
10:39 ET | 200 | 11.065 |
10:42 ET | 800 | 11.01 |
10:44 ET | 655 | 11.03 |
10:46 ET | 1000 | 11.05 |
10:48 ET | 344 | 11.075 |
10:50 ET | 1948 | 11.05 |
10:55 ET | 600 | 11.07 |
10:57 ET | 3291 | 11.02 |
11:00 ET | 400 | 11 |
11:02 ET | 346 | 11.01 |
11:04 ET | 2755 | 10.97 |
11:06 ET | 200 | 10.93 |
11:08 ET | 1400 | 10.925 |
11:09 ET | 1056 | 10.91 |
11:11 ET | 1800 | 10.9 |
11:13 ET | 100 | 10.89 |
11:15 ET | 900 | 10.88 |
11:18 ET | 400 | 10.89 |
11:20 ET | 2100 | 10.89 |
11:22 ET | 200 | 10.87 |
11:24 ET | 400 | 10.9 |
11:27 ET | 400 | 10.9 |
11:29 ET | 675 | 10.935 |
11:31 ET | 2154 | 10.92 |
11:33 ET | 100 | 10.92 |
11:36 ET | 600 | 10.88 |
11:40 ET | 2057 | 10.87 |
11:44 ET | 324 | 10.87 |
11:45 ET | 1100 | 10.895 |
11:47 ET | 500 | 10.89 |
11:49 ET | 2499 | 10.9025 |
11:54 ET | 300 | 10.9025 |
11:56 ET | 506 | 10.86 |
12:00 ET | 40757 | 10.81 |
12:02 ET | 512 | 10.81 |
12:03 ET | 3133 | 10.845 |
12:05 ET | 500 | 10.8313 |
12:07 ET | 150 | 10.85 |
12:09 ET | 993 | 10.89 |
12:12 ET | 1088 | 10.92 |
12:14 ET | 300 | 10.88 |
12:16 ET | 1000 | 10.88 |
12:18 ET | 450 | 10.84 |
12:20 ET | 785 | 10.85 |
12:21 ET | 800 | 10.85 |
12:23 ET | 600 | 10.85 |
12:25 ET | 300 | 10.83 |
12:27 ET | 800 | 10.79 |
12:30 ET | 3000 | 10.74 |
12:32 ET | 700 | 10.72 |
12:34 ET | 10736 | 10.65 |
12:36 ET | 895 | 10.67 |
12:38 ET | 100 | 10.675 |
12:39 ET | 40679 | 10.68 |
12:41 ET | 2409 | 10.735 |
12:43 ET | 3209 | 10.695 |
12:45 ET | 6633 | 10.68 |
12:48 ET | 3332 | 10.68 |
12:50 ET | 100 | 10.66 |
12:52 ET | 300 | 10.65 |
12:54 ET | 5009 | 10.64 |
12:56 ET | 600 | 10.61 |
12:57 ET | 23357 | 10.5101 |
12:59 ET | 24729 | 10.51 |
01:01 ET | 11052 | 10.4507 |
01:03 ET | 1593 | 10.43 |
01:06 ET | 5000 | 10.425 |
01:08 ET | 1400 | 10.421 |
01:10 ET | 2201 | 10.46 |
01:12 ET | 600 | 10.455 |
01:14 ET | 697 | 10.47 |
01:15 ET | 4446 | 10.47 |
01:17 ET | 1548 | 10.4888 |
01:19 ET | 500 | 10.49 |
01:21 ET | 1680 | 10.48 |
01:24 ET | 2996 | 10.46 |
01:26 ET | 3005 | 10.45 |
01:28 ET | 4985 | 10.485 |
01:33 ET | 5100 | 10.4799 |
01:37 ET | 10715 | 10.425 |
01:39 ET | 1132 | 10.425 |
01:42 ET | 2473 | 10.42 |
01:44 ET | 1665 | 10.4493 |
01:46 ET | 3705 | 10.425 |
01:48 ET | 11549 | 10.445 |
01:50 ET | 500 | 10.43 |
01:51 ET | 600 | 10.43 |
01:53 ET | 398 | 10.4325 |
01:55 ET | 1284 | 10.45 |
01:57 ET | 2300 | 10.48 |
02:02 ET | 2185 | 10.47 |
02:04 ET | 300 | 10.47 |
02:06 ET | 2013 | 10.46 |
02:08 ET | 3006 | 10.44 |
02:09 ET | 1311 | 10.45 |
02:11 ET | 5847 | 10.41 |
02:13 ET | 3185 | 10.4 |
02:15 ET | 2365 | 10.42 |
02:18 ET | 5044 | 10.4099 |
02:20 ET | 1083 | 10.42 |
02:22 ET | 11388 | 10.47 |
02:24 ET | 100 | 10.47 |
02:26 ET | 1200 | 10.47 |
02:27 ET | 400 | 10.46 |
02:29 ET | 1653 | 10.45 |
02:33 ET | 300 | 10.45 |
02:36 ET | 3801 | 10.44 |
02:38 ET | 586 | 10.45 |
02:40 ET | 1547 | 10.44 |
02:42 ET | 3350 | 10.41 |
02:44 ET | 100 | 10.4117 |
02:45 ET | 537 | 10.41 |
02:47 ET | 1636 | 10.41 |
02:49 ET | 3406 | 10.36 |
02:51 ET | 250 | 10.3578 |
02:54 ET | 2996 | 10.39 |
02:56 ET | 200 | 10.38 |
02:58 ET | 819 | 10.36 |
03:00 ET | 2218 | 10.31 |
03:02 ET | 2658 | 10.33 |
03:03 ET | 12436 | 10.26 |
03:05 ET | 400 | 10.3 |
03:07 ET | 755 | 10.31 |
03:09 ET | 2693 | 10.295 |
03:12 ET | 799 | 10.32 |
03:14 ET | 900 | 10.28 |
03:16 ET | 523 | 10.27 |
03:18 ET | 1855 | 10.28 |
03:20 ET | 1546 | 10.25 |
03:21 ET | 1750 | 10.21 |
03:23 ET | 6018 | 10.1675 |
03:25 ET | 8733 | 10.22 |
03:27 ET | 3091 | 10.28 |
03:30 ET | 1952 | 10.28 |
03:32 ET | 4412 | 10.33 |
03:34 ET | 570 | 10.35 |
03:36 ET | 2100 | 10.3 |
03:38 ET | 3603 | 10.35 |
03:39 ET | 18661 | 10.3 |
03:41 ET | 4528 | 10.31 |
03:43 ET | 6500 | 10.285 |
03:45 ET | 1880 | 10.32 |
03:48 ET | 2416 | 10.3 |
03:50 ET | 3591 | 10.3 |
03:52 ET | 3244 | 10.345 |
03:54 ET | 3390 | 10.34 |
03:56 ET | 8081 | 10.37 |
03:57 ET | 18575 | 10.395 |
03:59 ET | 207169 | 10.46 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 391.4M | -2.9x | --- |
LENZ Therapeutics Inc | 395.5M | -1.0x | --- |
ACELYRIN Inc | 404.0M | -1.6x | --- |
Aura Biosciences Inc | 372.1M | -3.9x | --- |
Fibrobiologics Inc | 424.0M | -11.9x | --- |
Neurogene Inc | 432.8M | -7.4x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $391.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.